AstraZeneca Q3 Results - Q3 Top Pharma Company Earnings Reports

View AstraZeneca's Q3 Earnings Report

FiercePharma says: AstraZeneca posted strong third-quarter numbers and boosted its full-year forecast by a whopping 40 cents per share. But one of the biggest pieces of news to come out of the company's Q3 report is a $520 million tentative agreement with the U.S. Attorney's Office in Philadelphia. Like several other drugmakers who've announced big settlements this year, AstraZeneca was facing a probe into alleged off-label marketing of a drug. In this case, the antipsychotic Seroquel. Read more of our coverage here...


  • US sales of Toprol-XL, benefiting from withdrawal of generic products, accounted for 3 percent of global revenue growth at CER.
  • US sales of Novel Influenza A (H1N1) vaccine totalled $152 million in the third quarter, accounting for 2 percent of global revenue growth at CER.
  • Emerging Markets revenue was up 15 percent at CER; on track for double-digit growth for the full year.

Check out AZ's current earnings estimates from CNN Money

AZ's Website:

AstraZeneca Q3 Results - Q3 Top Pharma Company Earnings Reports

Suggested Articles

After more than 10 years as partners, Sanofi and Regeneron are splitting up their deal to comarket PCSK9 med Praluent and immunology drug Kevzara.

Fujifilm has completed the first manufacturing facility in Japan to make drug-delivering liposomes to use for cancer fighting drugs it is developing.

J&J chief Alex Gorsky has assured plenty of critics that its talc products are safe, but he's not interested in explaining to Congress.